Premier Biomedical Inc. Fact Sheet.
? Premier Biomedical (PBI) is a publicly traded research-based company that intends to
discover and develop medical treatments targeting the treatment of heretofore incurable
and/or hard-to-cure diseases.
? The Company’s proprietary Sequential Dialysis Technique is a methodology that physically
removes the pathophysiologic basis of the disease, eliminating it without dangerous side
effects.
o Superior to current treatments which eliminate the presence of most illnesses but
often with catastrophic or even fatal side effects.
o Subtractive therapy (removal of harmful molecules) reduces risks associated with
conventional “Additive” therapy (adding chemicals to the body).
o Targets Cancer, Leukemia, Cockayne Syndrome, Neurofibromatosis, Fibromyalgia,
Multiple Sclerosis, and Atherosclerosis – collectively over $700 billion market
opportunity.
? Developed a proprietary patented drug candidate, Feldetrex™ as a potential treatment for
Fibromyalgia, neuropathic pain, and chemical addiction.
o Expected to deliver significant relief to patients, while presenting fewer side effects
than other alternate medications.
o The annual market size of all proposed market segments for Feldetrex™ is over $20
billion.
o The company strategy is to use the sales of Feldetrex™ to provide short term
revenue and to fund technology.
? Penn Biomedical Group (PBG) study analyzed potential market for Feldetrex versus
entrenched competition, Lyrica and Cymbalta, whose sales exceed $10B currently.
? The Company has established two outstanding research partnerships with the University of
Texas, El Paso (UTEP) and the Department of Defense
o Leverage the substantial infrastructure and resourced capacity of these
organizations to perform experimentation and to engage in product development in
an inexpensive and efficient manner.
o UTEP contractually owns 10% of PBI profits associated with their direct participation
programs. The DoD contractually can receive medications at PBI cost.
o Superior results in animal testing of proprietary immunotherapy cancer antibody
treatments targeting cancer antigens CTLA-4, PD-1, and BTLA protein activities.
? A second PBG study examined anti-cancer drug potential sales, indicating a potential
revenue of $1.9 B.
? In order to establish short term revenue to finance on-going research, the Company has
initiated efforts to establish Joint Ventures with established pharmaceutical firms in South
America & Asia to develop, manufacture and distribute Premier Biomedical’s treatments and
drugs. Press releases announcing these joint ventures will be issued shortly.
? An outside healthcare market advisor in Brazil forecasted potential sales of PBI products in
South America of $400M per year by 2020.
